NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners ...

GBS, Inc. (NASDAQ:GBS) has received institutional review board (IRB) approval to enroll subjects for its time-course glucose evaluation study which will clinically validate the time course of glucose.

Mumbai: The Minister of Medical Education, Hasan Mushrif, on Tuesday called for the effective implementation of Standard Operating Procedures (SOPs) to curb the spread of the Guillain-Barré Syndrome ...

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market the BD MAX™ GBS ...

BD (Becton, Dickinson and Company) (NYSE: BDX) announced today the U.S. Food and Drug Administration (FDA) clearance of the BD MAX™ Group B Streptococcus (GBS) Assay and Clinical Laboratory ...